Maze Therapeutics
CA - South SFBiotechnology
Focus: Maze Therapeutics is an early-stage biotech focused on small molecules, gene therapy, antisense oligonucleotides, and biologics, headquartered in South San Francisco. The company is in discovery/early clinical phase with minimal revenue-generating activity.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Total Funding
$115M
Open Jobs
9-4 this month
Stable — net -4 jobs in 30d
4 added, 8 removed. Backfill posture.
Should You Work at Maze Therapeutics?
AI assessmentMaze is a high-risk, high-reward pre-revenue biotech best suited for career-stage scientists willing to trade stability for modality expertise and equity participation in an early-stage bet.
Why Work Here
- Opportunity to work on cutting-edge modalities (gene therapy, antisense) at a focused biotech during inflection point — hiring 13 active roles signals pipeline advancement
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
MZE001
HealthyClinical Trials (1)
NCT05249621A Randomized Phase 1 of of MZE001 in Healthy Volunteers
Phase 1Help build intelligence for Maze Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.